279 related articles for article (PubMed ID: 11479393)
1. SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study.
Dell'Agnello G; Ceravolo R; Nuti A; Bellini G; Piccinni A; D'Avino C; Dell'Osso L; Bonuccelli U
Clin Neuropharmacol; 2001; 24(4):221-7. PubMed ID: 11479393
[TBL] [Abstract][Full Text] [Related]
2. The SSRI, citalopram, improves bradykinesia in patients with Parkinson's disease treated with L-dopa.
Rampello L; Chiechio S; Raffaele R; Vecchio I; Nicoletti F
Clin Neuropharmacol; 2002; 25(1):21-4. PubMed ID: 11852292
[TBL] [Abstract][Full Text] [Related]
3. Fluoxetine does not impair motor function in patients with Parkinson's disease: correlation between mood and motor functions with plasma concentrations of fluoxetine/norfluoxetine.
Kostić V; Dzoljić E; Todorović Z; Mijajlović M; Svetel M; Stefanova E; Dragasević N; Petrović I; Milosević M; Kovacević I; Miljković B; Pokrajac M; Prostran M
Vojnosanit Pregl; 2012 Dec; 69(12):1067-75. PubMed ID: 23424961
[TBL] [Abstract][Full Text] [Related]
4. Influence of baseline severity on the effects of SSRIs in depression: an item-based, patient-level post-hoc analysis.
Hieronymus F; Lisinski A; Nilsson S; Eriksson E
Lancet Psychiatry; 2019 Sep; 6(9):745-752. PubMed ID: 31303567
[TBL] [Abstract][Full Text] [Related]
5. Motor changes during sertraline treatment in depressed patients with Parkinson's disease*.
Kulisevsky J; Pagonabarraga J; Pascual-Sedano B; Gironell A; García-Sánchez C; Martínez-Corral M
Eur J Neurol; 2008 Sep; 15(9):953-9. PubMed ID: 18637826
[TBL] [Abstract][Full Text] [Related]
6. Selective serotonin re-uptake inhibitors decrease the cytokine-induced endothelial adhesion molecule expression, the endothelial adhesiveness to monocytes and the circulating levels of vascular adhesion molecules.
Lekakis J; Ikonomidis I; Papoutsi Z; Moutsatsou P; Nikolaou M; Parissis J; Kremastinos DT
Int J Cardiol; 2010 Mar; 139(2):150-8. PubMed ID: 19004511
[TBL] [Abstract][Full Text] [Related]
7. SSRIs in the treatment of depression in Parkinson's disease.
Leentjens AF; Vreeling FW; Luijckx GJ; Verhey FR
Int J Geriatr Psychiatry; 2003 Jun; 18(6):552-4. PubMed ID: 12789682
[No Abstract] [Full Text] [Related]
8. [Use of antidepressant drugs in schizophrenic patients with depression].
Micallef J; Fakra E; Blin O
Encephale; 2006; 32(2 Pt 1):263-9. PubMed ID: 16910628
[TBL] [Abstract][Full Text] [Related]
9. Paroxetine in Parkinson's disease: effects on motor and depressive symptoms.
Ceravolo R; Nuti A; Piccinni A; Dell'Agnello G; Bellini G; Gambaccini G; Dell'Osso L; Murri L; Bonuccelli U
Neurology; 2000 Oct; 55(8):1216-8. PubMed ID: 11071504
[TBL] [Abstract][Full Text] [Related]
10. Mortality Risk Among Patients With COVID-19 Prescribed Selective Serotonin Reuptake Inhibitor Antidepressants.
Oskotsky T; Maric I; Tang A; Oskotsky B; Wong RJ; Aghaeepour N; Sirota M; Stevenson DK
JAMA Netw Open; 2021 Nov; 4(11):e2133090. PubMed ID: 34779847
[TBL] [Abstract][Full Text] [Related]
11. Using secondary binding properties to select a not so selective serotonin reuptake inhibitor.
Stahl SM
J Clin Psychiatry; 1998 Dec; 59(12):642-3. PubMed ID: 9921697
[No Abstract] [Full Text] [Related]
12. [Selective serotonin reuptake inhibitors--current knowledge].
Dudek D; Zieba A; Siwek M; Wróbel A
Psychiatr Pol; 2004; 38(3):507-24. PubMed ID: 15199659
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs.
Nemeroff CB; Entsuah R; Benattia I; Demitrack M; Sloan DM; Thase ME
Biol Psychiatry; 2008 Feb; 63(4):424-34. PubMed ID: 17888885
[TBL] [Abstract][Full Text] [Related]
14. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression.
Thase ME; Nierenberg AA; Vrijland P; van Oers HJ; Schutte AJ; Simmons JH
Int Clin Psychopharmacol; 2010 Jul; 25(4):189-98. PubMed ID: 20531012
[TBL] [Abstract][Full Text] [Related]
15. The effect of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics and metabolism of perazine in the rat.
Daniel WA; Syrek M; Haduch A; Wójcikowski J
J Pharm Pharmacol; 2001 Apr; 53(4):449-61. PubMed ID: 11341361
[TBL] [Abstract][Full Text] [Related]
16. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension-type headache in adults.
Banzi R; Cusi C; Randazzo C; Sterzi R; Tedesco D; Moja L
Cochrane Database Syst Rev; 2015 May; 2015(5):CD011681. PubMed ID: 25931277
[TBL] [Abstract][Full Text] [Related]
17. Sertraline and fluoxetine: safe treatments for children and adolescents with epilepsy and depression.
Thomé-Souza MS; Kuczynski E; Valente KD
Epilepsy Behav; 2007 May; 10(3):417-25. PubMed ID: 17306625
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Traditional Chinese Medicine Combined with Selective Serotonin Reuptake Inhibitors on the Treatment for Parkinson's Disease with Depression: A Systematic Review and Meta-Analysis.
Feng ST; Wang XL; Wang YT; Yuan YH; Li ZP; Chen NH; Wang ZZ; Zhang Y
Am J Chin Med; 2021; 49(3):627-643. PubMed ID: 33657988
[TBL] [Abstract][Full Text] [Related]
19. Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline.
Stahl SM
Biol Psychiatry; 2000 Nov; 48(9):894-901. PubMed ID: 11074227
[TBL] [Abstract][Full Text] [Related]
20. Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline.
Waldinger MD; Hengeveld MW; Zwinderman AH; Olivier B
J Clin Psychopharmacol; 1998 Aug; 18(4):274-81. PubMed ID: 9690692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
